GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bionet 1784.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

46.50

+1.31%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bionet

Its shares trade on Taipei Exchange under the ticker 1784.TWO. It has been listed since 17 September 2004. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.24bn and net income of TWD 51.4m. At that date it held total assets of TWD 3.08bn and shareholders' equity of TWD 1.27bn.

Bionet Corp. engages in the businesses of cell therapy, regenerative medicine and medical big data. The company is headquartered in Taipei City, Taipei. The company went IPO on 2004-09-17. The Company’s main products include umbilical cord blood stem cells, mesenchymal stem cells, adult peripheral blood stem cells and others. The firm also provides precision medical application, prenatal testing and genetic testing services. The firm operates its businesses mainly in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
17 Sept 2004
Employees
118

Leadership

Pay as last reported

  • Mr. Cheng-Hsien TsaiChairman of the Board, since 2000
  • Mr. Qingyuan KangGeneral Manager
  • Huixin HuangDeputy General Manager-Marketing
  • Qianyu LiuHead of Finance & Accounting
  • Mingzhong YuCorporate Governance Officer
  • Mr. Shiming LiangDirector
  • Ms. Cuiru ZhangDirector
  • Mr. Handong ZhangDirector
  • Mr. Wenzheng ZhangDirector
  • Mr. Shao-Hua HuangIndependent Director
  • Mr. Pao-Shi ShengIndependent Director
  • Mr. Wenxi YanIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Bionet Corp. offers umbilical cord blood stem cells as a key product in Health Care sector.
  • The company provides mesenchymal stem cells and adult peripheral blood stem cells for regenerative medicine.
  • Bionet Corp. operates primarily in the domestic market with a focus on medical big data services.

Weaknesses

  • Bionet Corp. has limited international presence beyond the domestic market.
  • The company's employee count of 118 may restrict scalability in Health Care sector.
  • Bionet Corp. relies heavily on domestic market for its revenue streams.

Opportunities

  • Expanding into regenerative medicine applications for global Health Care markets.
  • Increasing demand for precision medical applications in Taiwan's Health Care sector.
  • Growing market for genetic testing services in the domestic Health Care industry.

Threats

  • Competition from other Health Care firms in Taiwan's domestic market.
  • Regulatory changes affecting medical big data usage in Taiwan.
  • Economic downturns impacting domestic Health Care spending in Taiwan.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.